about
Animal models of myasthenia gravis: utility and limitationsThe role of adenosinergic pathway in human autoimmune diseasesVaccines against myasthenia gravis.Deficits in endogenous adenosine formation by ecto-5'-nucleotidase/CD73 impair neuromuscular transmission and immune competence in experimental autoimmune myasthenia gravis.Protection against experimental autoimmune myocarditis is mediated by interleukin-10-producing T cells that are controlled by dendritic cellsInflammation in central nervous system injuryPoly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitisAcute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.Development of novel therapies for MG: Studies in animal models.Novel treatment for immune neuropathies on the horizon.Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?Physical Exercise Attenuates Experimental Autoimmune Encephalomyelitis by Inhibiting Peripheral Immune Response and Blood-Brain Barrier Disruption.Animal models of antimuscle-specific kinase myasthenia.Rapamycin alleviates inflammation and muscle weakness, while altering the Treg/Th17 balance in a rat model of myasthenia gravis.Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis.
P2860
Q26750632-7831C582-6DEE-4C2A-BD80-8909535FC946Q28069199-45B1C27D-2711-4475-843F-586AA995A8DAQ34433908-F6EB80CE-3F13-4848-A701-4708E96A1EF8Q35067400-39EF517C-6A6B-4AD3-8465-2B69EC93DD20Q35084902-57D64ADA-2CAE-459F-A636-97689D5FD22BQ35213716-14DC3C29-B6A0-4600-A60E-3471E1AED614Q36808573-FDDA9362-15C1-4F22-9215-D01BD8510CFCQ37561515-2B7F3C56-4445-49EF-8C28-32807C954445Q37713733-86E14E58-190F-41D1-ABA6-9A137C2CE0D0Q37892641-D833AA9A-5691-4D2A-9FCF-C7D86AE67659Q37967185-84C90CB0-2C29-46E3-A1DB-5ABB744550CBQ39570654-9FBAE9B9-C1CE-4779-89A3-54D616A259A8Q41846302-953A2736-74EC-4477-8FAF-00094D4D8594Q42334836-DA96C151-292A-40E1-95DB-9B0F09B4EB01Q45118454-2439BB9E-F3B2-4111-BC4A-8F4044E81D24
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Rat models as tool to develop new immunotherapies.
@ast
Rat models as tool to develop new immunotherapies.
@en
Rat models as tool to develop new immunotherapies.
@nl
type
label
Rat models as tool to develop new immunotherapies.
@ast
Rat models as tool to develop new immunotherapies.
@en
Rat models as tool to develop new immunotherapies.
@nl
prefLabel
Rat models as tool to develop new immunotherapies.
@ast
Rat models as tool to develop new immunotherapies.
@en
Rat models as tool to develop new immunotherapies.
@nl
P1476
Rat models as tool to develop new immunotherapies.
@en
P304
P356
10.1034/J.1600-065X.2001.1840111.X
P577
2001-12-01T00:00:00Z